AB2 Bio

company

About

AB2 Bio is a drug discovery and development company.

  • Lausanne,Vaud,Switzerland
  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
Fr58M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

AB2 Bio Ltd located at the innovation park of the école polytechnique fédérale de lausanne (epfl), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases with large unmet medical needs inflammation is a natural defense mechanism.
However, dysregulated and persistent inflammatory processes are the basis of several chronic inflammatory and autoimmune diseases, such as: nlrc4 - mas, adult onset still's disease, chronic obstructive pulmonary disease and many others ab2 bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based diseases extensive phase i and ib clinical trials demonstrated a high tolerance and an excellent safety profile of their drug.
They have advanced clinical programs in nlrc4 mas and in adult onset still’s disease.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Fr58M
AB2 Bio has raised a total of Fr58M in funding over 2 rounds. Their latest funding was raised on Jan 14, 2016 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 14, 2016 Series B Fr58M Detail

Employee Profiles

Number of Employee Profiles
10
AB2 Bio has 10 current employee profiles, including Board member Benedict Hentsch
Board member
Executive
Board member
Board member
Board member